A European Medicines Agency (EMA) committee has issued a positive opinion recommending the approval of Fasenra (benralizumab) as an add-on treatment for adults with hard-to-treat eosinophilic granulomatosis with polyangiitis (EGPA). If approved for the recommended indication, the AstraZeneca therapy would be a new option for patients in…
Rituximab may be associated with a higher risk of serious adverse events, particularly infections, in people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Time to first serious adverse event, as well as to second and multiple serious adverse events, is significantly shorter for patients treated with rituximab…
ANCA-associated vasculitis (AAV) patients treated with rituximab are up to four times more likely to develop hypogammaglobulinemia (HGG), or low blood levels of antibodies that help fight off infections, than people with other autoimmune conditions. That’s according to a real-world study in China that also found that higher…
Treatment with rituximab is superior to cyclophosphamide at inducing disease remission in people with granulomatosis with polyangiitis (GPA), according to a single-center study in Iran. While the safety profiles of the two therapies were comparable, treatment with rituximab was more effective, the study found. Specifically, about 90% of…
About a quarter of people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) under maintenance treatment with rituximab experience relapses, mainly during the first two years. That’s according to a real-world study in Greece that looked at data from 101 people with GPA or MPA, the two most common…
People with ANCA-associated vasculitis (AAV) have an 83% higher risk of developing cardiovascular and cerebrovascular diseases (CCVD) relative to those without vasculitis, according to a review study that also showed the risk was significantly higher in the first two years after an AAV diagnosis. “These findings underline the importance…
Researchers have identified a set of clinical red flags that could help detect eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV). Among the red flags are specific high-level thresholds of eosinophils, a type of immune cell, combined with other signs including asthma, nasal polyps,…
Eye symptoms related to ANCA-associated vasculitis (AAV) are most common among those with granulomatosis with polyangiitis (GPA), affecting more than one-third of these patients, a new study from China showed. “These insights collectively underscore the importance of consistent ocular [eye-related] assessments for AAV patients, enabling the monitoring of disease…
Adding Tavneos (avacopan) to standard maintenance treatment safely and effectively promotes disease remission in ANCA-associated vasculitis (AAV) patients, according to a real-world study involving five German centers. In fact, remission rates after one year of Tavneos treatment were higher than those reported in the Phase 3 ADVOCATE…
Using benralizumab — a medication approved in the U.S. for a rare type of asthma — off-label as an add-on to standard induction treatment resulted in a high rate of disease remission in people with eosinophilic granulomatosis with polyangiitis (EGPA) and severe asthma. That’s according to a real-world study in…
Get regular updates to your inbox.